By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at

Key Statistics

Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN



Company News
Medivation, Inc. (MDVN) Announces First Quarter 2015 Financial Results Teleconference On May 7, 2015 4/27/2015 10:21:17 AM
Tokai Pharmaceuticals (TKAI) Announces The Appointment Of Cheryl Cohen, Former Medivation, Inc. (MDVN) Chief Commercial Officer, To Its Board Of Directors 4/14/2015 11:26:36 AM
Medivation, Inc. (MDVN) Release: Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial 4/2/2015 11:31:26 AM
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented During Plenary Presentations At The 2015 European Association Of Urology Congress 3/24/2015 9:42:26 AM
Medivation, Inc. (MDVN) Release: New Enzalutamide Data To Be Presented In Late Breaking News Plenary Session At European Association Of Urology Congress 3/17/2015 1:04:23 PM
Medivation, Inc. (MDVN) Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update 2/26/2015 11:47:13 AM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 2/25/2015 1:56:04 PM
Medivation, Inc. (MDVN) Announces Fourth Quarter And Year-End 2014 Financial Results Teleconference On February 25, 2015 2/11/2015 3:18:00 PM
Medivation, Inc. (MDVN) Release: Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase In PFS As Compared To Bicalutamide In Metastatic Prostate Cancer 1/22/2015 11:22:58 AM
Medivation, Inc. (MDVN) Exercises License Option For Pidilizumab 12/24/2014 10:11:08 AM